Northern Trust Corp Has $21.70 Million Stake in Heron Therapeutics Inc (HRTX)

Northern Trust Corp decreased its stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 0.8% during the fourth quarter, Holdings Channel reports. The fund owned 836,535 shares of the biotechnology company’s stock after selling 6,365 shares during the period. Northern Trust Corp’s holdings in Heron Therapeutics were worth $21,701,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Cohen Capital Management Inc. increased its holdings in shares of Heron Therapeutics by 0.6% during the 4th quarter. Cohen Capital Management Inc. now owns 141,780 shares of the biotechnology company’s stock valued at $3,678,000 after acquiring an additional 780 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Heron Therapeutics by 24.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 929 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Heron Therapeutics by 1.1% during the 4th quarter. Jennison Associates LLC now owns 229,626 shares of the biotechnology company’s stock valued at $5,956,000 after acquiring an additional 2,575 shares during the last quarter. Boston Advisors LLC increased its holdings in shares of Heron Therapeutics by 11.7% during the 4th quarter. Boston Advisors LLC now owns 24,740 shares of the biotechnology company’s stock valued at $642,000 after acquiring an additional 2,595 shares during the last quarter. Finally, Private Asset Management Inc. increased its holdings in shares of Heron Therapeutics by 2.9% during the 4th quarter. Private Asset Management Inc. now owns 93,882 shares of the biotechnology company’s stock valued at $2,435,000 after acquiring an additional 2,625 shares during the last quarter.

A number of research firms have issued reports on HRTX. BidaskClub lowered Heron Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, March 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price (down previously from $66.00) on shares of Heron Therapeutics in a report on Wednesday, January 16th. Cantor Fitzgerald lowered Heron Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, March 4th. ValuEngine lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, March 1st. Finally, Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $51.50.

Shares of NASDAQ:HRTX opened at $24.55 on Tuesday. Heron Therapeutics Inc has a 1-year low of $21.25 and a 1-year high of $42.90. The company has a market cap of $1.92 billion, a PE ratio of -10.06 and a beta of 1.56.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.17). Heron Therapeutics had a negative return on equity of 54.98% and a negative net margin of 230.84%. The firm had revenue of $28.84 million for the quarter, compared to analyst estimates of $28.05 million. Research analysts expect that Heron Therapeutics Inc will post -1.52 earnings per share for the current fiscal year.

WARNING: This article was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://sportsperspectives.com/2019/04/02/northern-trust-corp-has-21-70-million-stake-in-heron-therapeutics-inc-hrtx.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Story: What is dollar cost averaging (DCA)?

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.